| Autor: |
Sun X; Department of Molecular Microbiology and Immunology and., Nakajima E; Department of Molecular Microbiology and Immunology and., Norbrun C; Department of Molecular Microbiology and Immunology and.; Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, USA., Sorkhdini P; Department of Molecular Microbiology and Immunology and., Yang AX; Department of Molecular Microbiology and Immunology and., Yang D; Department of Molecular Microbiology and Immunology and., Ventetuolo CE; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA., Braza J; Providence VA Medical Center, Providence, Rhode Island, USA., Vang A; Providence VA Medical Center, Providence, Rhode Island, USA., Aliotta J; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA., Banerjee D; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA., Pereira M; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA., Baird G; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA., Lu Q; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA., Harrington EO; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA.; Providence VA Medical Center, Providence, Rhode Island, USA., Rounds S; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA.; Providence VA Medical Center, Providence, Rhode Island, USA., Lee CG; Department of Molecular Microbiology and Immunology and., Yao H; Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island, USA., Choudhary G; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA.; Providence VA Medical Center, Providence, Rhode Island, USA., Klinger JR; Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA., Zhou Y; Department of Molecular Microbiology and Immunology and. |
| Abstrakt: |
Chitinase 3 like 1 (CHI3L1) is the prototypic chitinase-like protein mediating inflammation, cell proliferation, and tissue remodeling. Limited data suggest CHI3L1 is elevated in human pulmonary arterial hypertension (PAH) and is associated with disease severity. Despite its importance as a regulator of injury/repair responses, the relationship between CHI3L1 and pulmonary vascular remodeling is not well understood. We hypothesize that CHI3L1 and its signaling pathways contribute to the vascular remodeling responses that occur in pulmonary hypertension (PH). We examined the relationship of plasma CHI3L1 levels and severity of PH in patients with various forms of PH, including group 1 PAH and group 3 PH, and found that circulating levels of serum CHI3L1 were associated with worse hemodynamics and correlated directly with mean pulmonary artery pressure and pulmonary vascular resistance. We also used transgenic mice with constitutive knockout and inducible overexpression of CHI3L1 to examine its role in hypoxia-, monocrotaline-, and bleomycin-induced models of pulmonary vascular disease. In all 3 mouse models of pulmonary vascular disease, pulmonary hypertensive responses were mitigated in CHI3L1-null mice and accentuated in transgenic mice that overexpress CHI3L1. Finally, CHI3L1 alone was sufficient to induce pulmonary arterial smooth muscle cell proliferation, inhibit pulmonary vascular endothelial cell apoptosis, induce the loss of endothelial barrier function, and induce endothelial-mesenchymal transition. These findings demonstrate that CHI3L1 and its receptors play an integral role in pulmonary vascular disease pathobiology and may offer a target for the treatment of PAH and PH associated with fibrotic lung disease. |
